MTB vs ZYME · P/E 12, $30.99B cap vs rev $76.3M
M&T Bank Corporation (MTB) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
M&T Bank Corporation (MTB) is a banks - regional company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
MTB does not have a complete income-statement cache yet.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
MTB currently screens at market cap $30.99B and trailing P/E 11.9. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the MTB and ZYME stock pages for the full models.
Not investment advice.